SciSparc Ltd. (NASDAQ:SPRC) Short Interest Update

SciSparc Ltd. (NASDAQ:SPRC) was the recipient of a significant decrease in short interest in the month of June. As of June 15th, there was short interest totaling 19,275 shares, a decrease of 94.9% from the May 31st total of 378,196 shares. Approximately 3.5% of the shares of the stock are sold short. Based on an average daily volume of 845,855 shares, the short-interest ratio is presently 0.0 days.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SciSparc in a research note on Tuesday, May 26th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, SciSparc has a consensus rating of “Sell”.

SciSparc Price Performance

NASDAQ:SPRC traded up $0.23 during mid-day trading on Thursday, reaching $6.09. 13,835 shares of the stock were exchanged, compared to its average volume of 648,667. The business has a fifty day moving average price of $6.89 and a 200 day moving average price of $7.67. SciSparc has a 1-year low of $2.98 and a 1-year high of $80.10.

SciSparc (NASDAQ:SPRC) last issued its quarterly earnings results on Wednesday, April 29th. The company reported ($31.60) earnings per share for the quarter. The business had revenue of $0.20 million for the quarter.

SciSparc Company Profile

SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.